Indivior Pharmaceuticals (INDV) reported $1.2B in revenue for fiscal 2025, +4.3% year on year. That ranks #1640 by revenue among 2853 SEC filers and #152 in Healthcare. Net income was $210M, a net margin of 16.9%. Revenue has grown 11.2% a year on average since 2022 ($901M then). The fiscal 2025 balance sheet shows $1.2B in total assets, $195M in cash and $290M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.2B | +4.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $994M | +3.9% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $262M | +589.5% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $210M | +2,900.0% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$27.0M | −$63.0M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $66.0M | +127.6% | FY20252025-12-31 |
| Total assetsAssets | $1.2B | −8.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$98.0M | +$239M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $195M | −38.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $290M | −7.9% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $317M | $89.0M | Open → |
| Q2 20262026-06-30 | $343M | $122M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 33 of 161 companies compared | 16.9% | |
| Operating marginRank 31 of 160 companies compared | 21.1% | |
| R&D as share of revenueRank 52 of 102 companies compared | 7.8% | |
| Cash as share of revenueRank 66 of 160 companies compared | 15.7% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Indivior Pharmaceuticals, Inc.
- Ticker
- INDV
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001625297
Filings
- 10-QAug 3, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| ProgynyPGNY | $1.3B | $58.5M |
| Curaleaf HoldingsCURLF | $1.3B | −$231M |
| Lakefront BiotherapeuticsLKFT | $1.3B | $363M |
| Indivior PharmaceuticalsINDV | $1.2B | $210M |
| Nasus PharmaNSRX | $1.2B | −$5.9M |
| Bio-TechneTECH | $1.2B | $73.4M |
| Trulieve CannabisTRLV | $1.2B | −$116M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Indivior Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/indivior-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Indivior Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/indivior-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-indivior-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Indivior Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/indivior-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-012237 · February 26, 2026
{{cite web |title=Indivior Pharmaceuticals — Key figures — 10-K (0001628280-26-012237) |url=https://www.sec.gov/Archives/edgar/data/1625297/000162828026012237/indv-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.